Cingulate publishes peer-reviewed pharmacokinetic study of ADHD candidate CTx-1301 in CNS Drugs

Findings support a once-daily, trimodal release profile intended to extend symptom coverage across the active day.

CTx-1301 showed fewer treatment-emergent adverse events than the reference product, despite a higher overall dose.

The publication follows a previously published Phase 3 efficacy and safety study, strengthening the clinical package ahead of potential commercialization.

Cingulate published a peer-reviewed pharmacokinetic analysis of CTx-1301 in CNS Drugs; results were presented in the publication.

The study found early-day drug exposure comparable to a reference dexmethylphenidate product, with higher exposure later in the day.